The authors concluded that the combination of venetoclax and chemotherapy shows promising efficacy in treating R/R T-ALL, suggesting that further studies are needed to explore the clinical benefits of BCL2 inhibitors in this context. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.